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More than 70 international delegates 
participated in the “by invitation only” 
EB 2006 Conference,* organized by 
DebRA UK and DebRA Ireland and 
held in Dublin in October 2006. Since 
DebRA’s last conference in 2000, excit-
ing progress has been made in trans-
forming a detailed knowledge of the 
fundamental molecular biology under-
lying the spectrum of genetic diseases 
known as epidermolysis bullosa (EB) 
into potential clinical applications. The 
conference aimed to review the cur-
rent state of the art, to identify barriers 
to further progress, and to identify new 
avenues for future research, as well 
as to derive a consensus among the 
research and clinical communities on 
priorities for future research and devel-
opment that will lead rapidly toward 
effective treatments. Researchers at the 
meeting reported the first case of suc-
cessful gene therapy for EB as well as 
several approaches to improve gene 
therapies with new cellular delivery 
methods and improved gene therapy 
vectors, and the intriguing possibility 
of protein therapy for EB.
EB is a complex group of genetic 
disorders producing various degrees of 
skin blistering and shearing. It affects 
about one in 17,000 live births, with 
an estimated 500,000 cases world-
wide. There are three main forms of 
the disease — EB simplex, junctional 
EB, and dystrophic EB — which are 
ascribed to mutations in ten well-
characterized genes expressed at the 
dermal–epidermal junction (J Uitto 
and G Richard, Clin Dermatol 23:33–
40, 2005).
Toward gene therapy
Michele De Luca (University of 
Modena, Italy, and Veneto Eye Bank 
Foundation, Venice, Italy) reported the 
first-ever successful gene therapy for 
EB. In a phase I/II clinical trial, he and 
his colleagues have “cured” areas of 
skin on the anterior thighs of a single, 
adult male patient with non-Herlitz 
junctional EB by transplanting several 
genetically modified epidermal sheets 
grown in culture onto both legs (a total 
of about 500 cm2). The epidermal sheets 
were grown from the patient’s own 
laminin 5-β3-chain-deficient epidermal 
stem cells taken from palm biopsies 
and transfected ex vivo with a retroviral 
vector expressing normal laminin 5-β3. 
The sheets were prepared by the same 
method as those already in use for the 
treatment of skin burns, and mucosal 
and corneal defects. The patient was 
a compound heterozygote expressing 
a low level of laminin 5 that is prob-
ably functional; he was selected for the 
trial because this basal level of protein 
production, the researchers believed, 
would protect against rejection of the 
graft. The grafts were applied to regions 
of the skin that were covered with sev-
eral nonhealing lesions. The Italian 
surgical team prepared deep wound 
beds to receive the grafts by diathermy 
under local anesthetic. They saw com-
plete epidermal regeneration of the 
patches on both legs after 8 days, and 
a normal-looking epidermis was main-
tained throughout the 1-year follow-
up, from which they conclude that the 
stem cells were maintained in culture 
and renewed in vivo. They observed 
no MHC class I-restricted immune 
response and no antibodies against 
laminin 5. This work was reported 
recently in a paper in Nature Medicine 
(F Mavilio et al., Nat Med 12:1397–
1402, 2007). Following on this “proof 
of principle,” De Luca’s team is plan-
ning the step-by-step replacement of 
a large proportion of this patient’s skin 
surface with genetically modified skin; 
they also plan to coordinate a Europe-
wide clinical trial with further patients.
Simply expressing the wild-type 
gene, as the Italian trial demonstrates, 
can work well for recessive mutations; 
however, the majority of the genetic 
defects in EB are dominant-negative 
mutations, meaning that a method 
must also be found to prevent expres-
sion of dominant mutants or to “dilute 
out” the dominant mutant with a large 
excess of normal protein. The teams of 
Irwin McLean (University of Dundee, 
UK) and Dennis Roop (Baylor College 
of Medicine, Houston, TX) have been 
working on such a strategy by using 
small interfering RNA to knock down 
expression of mutant keratin 14 in a 
mouse model of dominant EB simplex. 
They are trying three approaches: first, 
simply to knock down expression of 
the single mutant allele; second, to 
knock down both endogenous alleles 
and replace the mutant product by 
expressing a wild-type gene; and third, 
to switch on additional keratin genes to 
dilute out the mutant protein. They are 
currently developing vectors to express 
several short hairpin RNAs that are 
rapidly processed to small interfering 
RNAs that wipe out mutant keratin 14 
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gene expression. The same vector also 
expresses the normal keratin 14 gene, 
as well as a “fail-safe” mechanism to 
kill cells expressing the vector should 
anything go wrong. The problem of how 
to deliver such a construct to patients 
remains: an ex vivo approach like that 
of the genetically modified skin patches 
described above is being investigated in 
collaboration with De Luca, but it might 
also be possible to deliver it to skin cells 
in vivo using small-molecule vectors 
or viral vectors. Meanwhile, Roop has 
discovered, by using inducible mouse 
models for EB simplex and another 
keratin-based disease, epidermolytic 
hyperkeratosis, that simply increasing 
the ratio of wild-type to mutant keratin 
can ameliorate the disease phenotype. 
By coculturing epidermal stem cells 
expressing the wild-type protein with 
stem cells expressing the mutant pro-
tein, his team saw that cells expressing 
the wild-type protein have a selective 
advantage over cells expressing the 
mutant protein.
Improved gene therapies
Clinical trials for gene therapy have 
taken a setback since 2003, when two 
of the ten patients in a successful gene-
therapy trial for severe combined immu-
nodeficiency (M Cavazzana-Calvo et 
al., Science 288:669–72, 2000) devel-
oped leukemia. This was the result of 
insertional mutagenesis caused by the 
retroviral vector integrating into the 5′ 
untranslated region of an oncogene. 
In light of this risk, the United States 
National Institutes of Health has pro-
duced recommendations for the design 
of ideal gene therapy vectors. Alain 
Hovnanian (University of Toulouse, 
France) reported the progress he and his 
collaborators in a large trans-European 
collaborative project have made toward 
developing a new generation of safe, 
self-inactivating (SIN) retroviral vectors 
modeled on these recommendations. 
These SIN vectors are based on lentivi-
ruses, such as the human immunode-
ficiency virus, which tend to integrate 
into transcribed regions of genes rather 
than into the 5′ untranslated region. 
They contain SIN long terminal repeat 
sequences; a strong promoter spe-
cific for the gene they express, which 
can also impart tissue specificity to 
the transgene expression; and “insula-
tor” elements that prevent transcrip-
tion of neighboring DNA sequences 
and position effects such as silencing. 
Hovnanian’s team has used such a vec-
tor to restore collagen VII expression 
and dermis–epidermis adherence in 
vivo to grafts of reconstructed skin. They 
are now looking at the tumorigenicity 
and immunogenicity of cells corrected 
with these vectors.
Another significant challenge in gene 
therapy for EB is the systemic delivery 
of the therapeutic gene — not only to 
the skin, but also to the cells lining the 
mouth, the rest of the gastrointestinal 
tract, and other affected internal sites. 
One potential solution to this problem 
may come from work described at the 
conference by David Woodley and Mei 
Chen (University of Southern California, 
Los Angeles, CA), who have simply 
injected genetically corrected autolo-
gous fibroblasts expressing wild-type 
collagen VII into the tail veins of reces-
sive dystrophic EB mice with fresh skin 
wounds. From 1 to 8 weeks later, they 
saw the normal collagen VII protein pro-
duced by the corrected cells in the der-
mal-epidermal junction of the skin at the 
wound sites. The protein did not appear 
in unwounded skin, and when they 
expressed only the NC1 domain of col-
lagen VII, it also did not appear at wound 
sites, which suggests some specificity. It 
is not clear whether the genetically mod-
ified fibroblasts home to the wound sites 
where they produce normal collagen VII 
or whether the protein itself accumulates 
at these sites from the blood; however, 
Woodley’s and Chen’s teams have also 
discovered that mouse or human col-
lagen VII protein alone — purified from 
genetically corrected mouse fibroblasts 
— also appears in the dermal-epidermal 
junction of wounded skin after injection 
into the tail vein, where it appears to 
promote wound healing.
Although these remarkable observa-
tions generate further questions — the 
signal that attracts the genetically modi-
fied fibroblasts and the collagen VII pro-
tein needs to be identified, as does the 
mechanism of extravasation into the skin 
— these studies suggest that “protein 
therapy” and “cell therapy” approaches 
might be possible for EB as well as for 
ulcers and other skin wounds.
Woodley and Chen’s findings might 
not be so surprising in light of the report 
by Katsuto Tamai (University of Osaka, 
Japan). He and his team found that, in 
mice, bone marrow stem cells express-
ing green fluorescent protein also find 
their way into the skin, where they pre-
sumably differentiate to produce new 
skin cells. This may explain how the 
skin has enough stem cells to sustain 
the healing process throughout the life 
of a severely affected EB patient. The 
green fluorescent protein-expressing 
bone marrow cells also appeared in 
skin grafts from collagen VII-null mice 
engrafted onto the green fluorescent 
protein-expressing mice, and Tamai 
estimates that up to 40% of cells in 
these grafted skin patches came from 
the bone marrow. Genetically corrected 
bone marrow stem cells may, one day, 
offer another route to whole-body gene 
therapy for EB.
Wound care
On the basis of the observation that 
fibroblasts from healthy donors gener-
ally do not provoke a strong immune 
response but they do produce col-
lagen VII, Marcela Del Rio (Centro 
Comunitario de Sangre y Tejidos, 
Asturias, Spain) and her collaborators 
are developing a tissue-engineered 
“chimeric” skin equivalent, contain-
ing keratinocytes from dystrophic EB 
patients and healthy donor fibroblasts. 
They hope that the donor fibroblasts, 
although not immortal, will persist long 
enough, and will supply sufficient col-
lagen VII, to make the skin-equivalent 
graft useful therapeutically without pro-
voking rejection. Del Rio and her col-
leagues have a phase I/II clinical trial 
planned for 2007.
Paul Kemp (Intercytex, Cambridge, 
UK) described several products con-
taining autologous or allogeneic fibro-
blasts that are currently in clinical trials 
to treat chronic wounds. He outlined 
problems in the processes of manu-
facturing, transporting, storing, and 
using living-cell therapeutics, for which 
Intercytex and other companies are 
developing solutions. He emphasized 
the need to design products with these 
practical considerations in mind: to 
determine the clinical strategy for their 
use early in the development process, 
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accepting the idea of a “gradual emer-
gence of efficacy”; and to design the 
supply chain for the product during the 
clinical trials.
EB patients suffer chronic wounds, 
yet wound-management technology 
is still far from ideal. Edel O’Toole 
(Queen Mary’s School of Medicine and 
Dentistry, London, UK) spoke about 
recent progress in developing skin 
substitutes, and “smart” systems such 
as nanoparticles and microspheres 
to deliver growth factors, drugs, and/
or nucleic acids; as well as intensive 
work over the past 5 years on defensins 
(natural antimicrobial peptides) to treat 
infections. She was concerned that our 
knowledge of the role that factors such 
as stem cells, hypoxia, matrix metal-
loproteinases, and cytokines may play 
in EB wounds is still limited, and she 
indicated that wound healing in EB is a 
neglected research area.
Mark Ferguson (Renovo, Manchester, 
UK) described his team’s elegant work 
on wound healing in fetuses in utero 
that led to the discovery that trans-
forming growth factor-β3 (TGFβ3), 
which is high in fetal keratinocytes 
and fibroblasts but low in adults, dra-
matically improves the healing of sur-
gical scars. By contrast, TGFβ1 and 
TGFβ2, secreted from degranulating 
platelets and inflammatory cells, are 
low in fetal wounds, but high in adult 
wounds. Pharmacological suppres-
sion of TGFβ1 and TGFβ2, or addition 
of exogenous TGFβ3 to adult surgical 
wounds, mimics scar-free fetal healing 
and results in much-improved surgi-
cal scars. All three TGFβ isoforms bind 
the same receptor but induce different 
conformation changes in the receptor 
that, presumably, induce different sig-
naling cascades and attract different 
cell types to the wound. TGFβ3 plays 
a role in fibroblast migration; by using 
TGFβ3 to stimulate fibroblast migration 
into a healing wound, Ferguson and 
colleagues see a more normal “basket-
weave” structuring of fibroblasts and 
secreted extracellular matrix proteins, 
and reduced scarring. Although there 
is no evidence yet that TGFβ3 might 
improve wound healing in EB patients, 
this work highlights the need for more 
research on growth factors and signal-
ing cascades in EB wounds.
Drug discovery and development
Laurent Gagnoux (Institut National de 
la Santé et de la Recherche Médicale 
Unit 452, Faculty of Medicine, Nice, 
France) discussed matrix proteases and 
reminded the conference that, before 
the discovery of the genes affected in 
EB, these enzymes were the main focus 
of attention in EB research, and that they 
are implicated in the blistering process 
and tumor invasion. While analyzing 
the protein composition of junctional 
EB keratinocytes, he noticed that they 
lacked plasminogen activator inhibi-
tor type 1 (PAI-1), which inhibits the 
conversion of plasminogen to plasmin 
by urokinase-type plasminogen activa-
tor (uPA). Plasmin, a serine protease, 
degrades many blood proteins, nota-
bly fibrin clots, but it also degrades the 
basement membrane, and overactiva-
tion of the uPA enzymatic cascade pro-
duces a junctional EB-like phenotype 
in transgenic mice. As the uPA inhibi-
tor, PAI-1, appears to be absent from 
junctional EB keratinocytes, Gagnoux 
hypothesizes that inhibitors of uPA 
would help to control the symptoms of 
junctional EB. He is planning to test this 
hypothesis in cellular and mouse mod-
els of junctional EB, as well as to look at 
PAI-1 expression in keratinocytes from 
dystrophic EB patients.
In an attempt to identify drugs to 
treat EB simplex, McLean’s team in 
Dundee, with the help of the Dundee 
Drug Discovery Unit, are screening 
small-molecule libraries for proteins 
that switch on gene expression from the 
keratin 6a gene promoter, with a view 
to switching on this normal keratin gene 
in EB simplex patients to substitute for 
the defective keratins 5 and 14. They 
have already identified seven molecules 
that turn down the keratin 6a gene pro-
moter, which may be useful for treating 
other keratin-based diseases, but at the 
time of the conference they had not yet 
identified any upregulators. Academic 
researchers, McLean explained, may be 
willing to take on such “long-shot” drug 
discovery programs for rare diseases in 
which big pharmaceutical companies 
are unwilling to invest.
Marlene Haffner (Office of Orphan 
Products Development, United 
States Food and Drug Administration, 
Rockville, MD) expanded on this prob-
lem by describing moves in the United 
States and in Europe to facilitate the 
development of so-called “orphan” 
drugs and products. In the United 
States’s Orphan Drug Act of 1983, an 
orphan product is defined as a drug or 
other product intended to treat a disease 
that affects fewer than 200,000 people 
(about seven people per 10,000) in the 
United States; in the European Union’s 
equivalent act (2001), the definition 
applies to diseases that affect fewer 
than five people per 10,000 of the 
European Union population. Haffner 
described what criteria a product 
must meet to obtain orphan designa-
tion, which qualifies the sponsor of the 
product for tax credits and marketing 
incentives. She told the conference that 
about 1,500 products currently have 
orphan drug designation in the United 
States, of which 295 have received 
Food and Drug Administration approv-
al to treat about 15 million patients 
with rare diseases in the United States. 
Among these, three products have been 
approved for EB.
There is a problem not only with 
commercial investment in drug devel-
opment for rare diseases, but also in 
finding sufficient numbers of patients 
to participate in clinical trials. Here 
too, criteria for clinical trials of orphan 
drugs and products must be defined to 
assure their safety and efficacy. Brendan 
Buckley (European Centre for Clinical 
Trials in Rare Diseases, University 
College, Cork, Ireland) described these 
problems and spoke of the need for 
global registries of patients with rare 
diseases to help identify potential par-
ticipants in transnational clinical trials.
Diagnosis
Such global registries presuppose that 
the patients registered in them have 
an accurate diagnosis of their dis-
ease. Giovanna Zambruno (Istituto 
Dermopatico dell’Immacolata, Rome, 
Italy) talked about the procedures and 
difficulties involved in obtaining an 
accurate molecular diagnosis of the 
many subtypes of EB. A molecular 
diagnosis generally begins with immu-
nofluorescence and electron micros-
copy of tissues, followed by an analysis 
of the proteins and antigen mapping 
by immunofluorescence microscopy. 
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Subsequently, direct sequence analysis 
can detect almost 95% of mutations, but 
it is an expensive process, and it misses 
mutations in regulatory regions as well 
as large genomic rearrangements.
Birgit Lane (Centre for Molecular 
Medicine, Singapore) explained why the 
importance of accurate molecular diag-
nosis for the patient’s benefit should not 
be underestimated: it fills the “informa-
tion vacuum” for patients, helping them 
to come to terms with their disease, and 
it also helps in prognosis and improves 
genetic counseling for sufferers and car-
riers who wish to have children. Many 
of the mutation-based therapies that are 
being developed (the small interfering 
RNA approaches, for example) require 
knowledge of the specific mutations. 
Also, specific molecular diagnoses 
help researchers to understand disease 
mechanisms by developing animal 
and cell models, as well as looking at 
the biochemical properties of mutant 
proteins. Among EB simplex patients in 
the United Kingdom, she told the con-
ference, about 20% have not had the 
underlying mutation identified.
Hiroshi Shimizu (Hokkaido University 
Graduate School of Medicine, Sapporo, 
Japan) confirmed that skin biopsies are 
still one of the most important steps for 
the correct diagnosis of the EB subtype. 
Biopsies allow pathologists to identify 
which layer of the skin the lesion occurs 
in, and they enable the protein defi-
ciency to be identified with the use of 
monoclonal antibodies, thus allowing 
identification of candidate genes for fur-
ther mutation analysis. Shimizu demon-
strated how skin biopsies allow objec-
tive evaluation of the efficacy of treat-
ment in his team’s elegant studies of col-
lagen XVII-null mice — the first, long-
survived, transgenic model of junctional 
EB — in which the disease phenotype 
was cured by transfer of the human 
gene encoding collagen XVII.
Hiva Fassihi (St John’s Institute of 
Dermatology, St Thomas’ Hospital, 
London, UK) spoke about advances in 
prenatal diagnosis of EB for couples in 
which one or both partners are patients, 
or for couples who have already had 
one affected pregnancy. She described 
the possibilities and limitations of non-
invasive prenatal diagnosis on fetal cells 
in the maternal circulation, and also of 
free fetal DNA in the plasma fraction 
of maternal blood, which represents 
3 %–6% of the total DNA in maternal 
plasma. The latter technique is already 
being used for X-linked disorders, to 
check the fetal rhesus D status and for 
some paternally transmitted single-gene 
disorders. Alternatively, cells removed 
from eight- to ten-cell-stage (day 3) 
embryos produced by in vitro fertiliza-
tion have been used for preimplanta-
tion genetic diagnosis of a variety of 
conditions, including inherited skin fra-
gility. Recently, preimplantation genetic 
diagnosis assays have been developed 
for severe forms of EB with the use of 
whole-genome amplification of DNA 
from single blastomeres followed by 
multiplex PCR of microsatellite markers 
close to the corresponding EB genes. 
This new approach is known as pre-
implantation genetic haplotyping. The 
United Kingdom’s Human Fertilisation 
and Embryology Authority licensed 
specific preimplantation genetic haplo-
typing tests for the LAMA3 and LAMB3 
genes in junctional EB in 2006.
Squamous-cell carcinoma
It remains unclear why dystrophic EB 
patients develop squamous-cell carci-
noma (SCC) and why it is particularly 
aggressive. Ulrich Rodeck (Thomas 
Jefferson University, Philadelphia, PA) 
explained that the signaling pathways 
in sporadic SCC include EGFR, mito-
gen- activated protein kinases, phos-
phatidylinositol 3-kinase, and NF-κB, 
but whether these pathways also oper-
ate in the SCC seen in dystrophic EB is 
not known.
John Marshall (Barts and The London 
Queen Mary’s School of Medicine and 
Dentistry, London, UK) is looking at the 
role of the epithelium-specific integrin 
αvβ6 in SCC. This integrin is normally 
expressed during development and 
generally not in normal adult epithelia, 
but it is also expressed de novo during 
wound healing and during tumorigen-
esis of colon cancers and breast can-
cers, among others. Marshall reported 
that αvβ6 is also upregulated in SCC from 
dystrophic EB patients and that it pro-
motes tumor invasion in organ cultures. 
The mechanism by which αvβ6 promotes 
invasion may involve Cox-2, the enzyme 
that produces prostaglandins during 
inflammation, which is also upregu-
lated in SCC. Marshall is looking at the 
effects of antibodies against the integ-
rin’s ligand-binding site as well as Cox-2 
inhibitors on tumor growth in vivo.
Peter Marinkovich (Stanford 
University, Palo Alto, CA) is looking at 
the role of the basement membrane in 
SCC, specifically, the role of laminin 5, 
which is required for SCC development. 
Marinkovich and his team are currently 
investigating the structure–function rela-
tionships of laminin 5 domains — espe-
cially β3-chain and α3-chain domains 
— in cell migration and intracellular 
signaling. They find that a polyclonal 
antibody against the α3-chain G4– 5 
domain inhibits SCC growth in mice.
After the conference, an invited 
group of experts in dystrophic EB-linked 
SCC, chaired by Irene Leigh (University 
of Dundee, UK), met to brainstorm the 
main issues in fundamental and clini-
cal research into this disease. This Skin 
Cancer Task Force identified the need for 
an international tissue bank and a more 
coordinated approach to testing poten-
tial chemoprophylactics. They stressed 
the need for a strategy for identifying the 
genetic and protein changes that arise at 
various stages of carcinogenesis in nor-
mal and dystrophic EB patients. They 
also noted the need for good consensus 
models for metastasis and invasion.
By bringing together many of the 
world’s leading EB experts, this confer-
ence provided a valuable opportunity to 
exchange ideas on how best to move the 
field forward. Drawing on this impetus, 
DebRA intends to support the creation 
of further expert task forces address-
ing specific priorities for research and 
development. The next international 
DebRA conference, scheduled for 
2009, should see reports of new clinical 
therapies developed from the promising 
progress reported in Dublin.
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